

TAKEDA ONCOLOGY IS COMMITTED TO THE ADVANCEMENT OF INNOVATIVE THERAPIES: ONCOLOGY DEVELOPMENT PIPELINE

PROGRAM	DESCRIPTION	DISEASE(S) UNDER INVESTIGATION	PHASE 1	PHASE 2	PHASE 3
BRENTUXIMAB VEDOTIN¹	CD30 Antibody Drug Conjugate	Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma, Anaplastic Large Cell Lymphoma			
BRIGATINIB	ALK Inhibitor	Non-small Cell Lung Cancer			
IXAZOMIB	Proteasome Inhibitor	Multiple Myeloma, Amyloidosis			
LEUPRORELIN ACETATE²	LH-RH Agonist	Prostate Cancer, Breast Cancer, new formulation			
PANITUMUMAB³	Anti-EGFR Antibody	Colorectal Cancer			
PEVONEDISTAT	Nedd8-Activating Enzyme Inhibitor	High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia Solid Tumors			
PONATINIB⁴	BCR-ABL Inhibitor	Chronic Myeloid Leukemia Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia			
SAPANISERTIB (TAK-228)	TORC1/TORC2 Inhibitor	Breast Cancer, Renal Cell Carcinoma, Endometrial Cancer			
TAK-117	PI3K Alpha Inhibitor	Renal Cell Carcinoma, Endometrial Cancer			
TAK-659	SYK/FLT-3 Inhibitor	Lymphoma, Acute Myelogenous Leukemia Solid Tumors			
VEDOLIZUMAB	Anti- $\alpha 4\beta 7$ Antibody	Graft versus Host Disease			
TAK-243	Ubiquitin-Activating Enzyme Inhibitor	Solid Tumors			
TAK-522 (XMT-1522)⁵	HER2 Dolaflexin Antibody Drug Conjugate	Breast Cancer			
TAK-573	CD38-targeted IgG4 fused with attenuated IFN α	Multiple Myeloma			
TAK-580	Pan-Raf Inhibitor	Solid Tumors			
TAK-788 (AP32788)	EGFR/HER2 Inhibitor	Non-small Cell Lung Cancer			
TAK-931	CDC7 Inhibitor	Solid Tumors			
CABOZANTINIB²	MET, VEGF, AXL and RET Inhibitor	Renal Cell Carcinoma	Development in Preparation		
NIRAPARIB⁶	PARP Inhibitor	Solid Tumors	Development in Preparation		

All programs have Global Development Rights unless otherwise noted.

¹ Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. ² Japan Only. ³ Japan Only, In-Licensed. ⁴ Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories).

⁵ Ex-US, Ex-Canada. TAK-522 (XMT-1522) is co-developed by Takeda and Mersana Therapeutics, Inc. ⁶ Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia.